GSK vs RTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Mar 26, 2026

GSK

58.5
AI Score
VS
RTX Wins

RTX

60.0
AI Score

Investment Advisor Scores

GSK

59score
Recommendation
HOLD

RTX

60score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK RTX Winner
Forward P/E 20.4918 29.1545 GSK
PEG Ratio 0.4986 2.7774 GSK
Revenue Growth 6.2% 12.1% RTX
Earnings Growth 54.7% 8.3% GSK
Tradestie Score 58.5/100 60.0/100 RTX
Profit Margin 17.5% 7.6% GSK
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Frequently Asked Questions

Based on our detailed analysis, RTX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.